Immunoregulator
AssigneeBiotempt B.V.
InventorsNisar Ahmed Khan, Robbert Benner
Life of this patent
Estimating the term…
Abstract
The invention relates to the field of immunology, more specifically to the field of immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease or inflammatory disease. The invention provides among others an immunoregulator (NMPF), use of an NMPF in preparing a pharmaceutical composition for treating an immune-mediated disorder, a pharmaceutical composition and a method for treating an immune-mediated disorder.
Claims43
An immunoregulator obtainable or derivable from beta-HCG capable of regulating Th1 and/or Th2 cell activity.
The immunoregluator of any one of the preceding claims wherein at least one amino acid has been replaced by an alanine residue.
A pharmaceutical composition for treating an immune-mediated disorder, said pharmaceutical composition comprising an active component obtainable from a urinary metabolite of HCG capable of protecting a mouse against a lipopolysaccharide induced septic shock or diabetes or Experimental Auto-immune Encephalitis/multiple sclerosis.
A method for diagnosing a pregnancy related immune-mediated disorder, said method comprising determining in a biological sample from a female, the relative ratio of a relative long-chain peptide versus a relative short-chain peptide, said peptides derivable from breakdown of beta-HCG.
A method for diagnosing an immune-mediated disorder in a subject, said method comprising determining in a biological sample, the relative ratio of a septic shock enhancing peptide versus a septic shock decreasing peptide, said peptides being derivable from breakdown of beta-HCG.
A method for diagnosing an immune-mediated disorder in a subject, said method comprising determining in a biological sample, the relative ratio of a diabetes enhancing peptide versus a diabetes decreasing peptide, said peptides being derivable from breakdown of beta-HCG.
A method for diagnosing a cardiovascular disorder comprising determining in a biological sample, the relative ratio of a heart failure enhancing peptide versus a heart failure decreasing peptide, said peptides being derivable from breakdown of beta-HCG.
A method for selecting an immunoregulator, said method comprising determining a therapeutic effect of an immunoregulator by subjecting an animal prone to show signs of diabetes to a peptide composition or fraction thereof, and determining the development of diabetes in said animal.
A method for selecting an immunoregulator, said method comprising determining a therapeutic effect of an immunoregulator by subjecting an animal prone to show signs of septic shock to a peptide composition or fraction thereof and determining the development of septic shock in said animal.
Dependencies are inferred from the claim text.